anti- ADAM2 antibody FNab00141
Background:
Sperm surface membrane protein that may be involved in sperm-egg plasma membrane adhesion and fusion during fertilization. Could have a direct role in sperm-zona binding or migration of sperm from the uterus into the oviduct. Interactions with egg membrane could be mediated via binding between its disintegrin-like domain to one or more integrins receptors on the egg. This is a non catalytic metalloprotease-like protein.
Clonality:
polyclonal
Classification:
Primary antibody
Alternative names:
ADAM 2, ADAM metallopeptidase domain 2, ADAM2, Cancer/testis antigen 15, CRYN1, CRYN2, CT15, Fertilin subunit beta, FTNB, PH 30, PH 30b, PH30, PH30 beta
Specificity:
Human, Mouse
Host:
Rabbit
Isotype:
IgG
Immunogen:
ADAM metallopeptidase domain 2
Purification:
Immunogen affinity purified
Purity:
≥95% as determined by SDS-PAGE
Calculated molecular weight:
82 kDa, observed 45-65 kDa
Form:
liquid
Applications:
ELISA, WB
Recommended dilution:
WB: 1:500-1:5000
Storage:
PBS with 0.02% sodium azide and 50% glycerol pH 7.3,-20℃ for 12 months(Avoid repeated freeze / thaw cycles.)
More info:
Email: info@sobekbio.com
Orders:
Email: orders@sobekbio.com
Fine Biotech is an ISO9001:2008 Certified Company,offers a full line of quality research kits,which include ELISA Kits,related ELISA assistant reagents and more high quality antibodies, recombinant proteins. Fine Biotech technical support are delicated to providing with professional and friendly assistance for our customers. Strict and multiple quality control ensure that our products continue to successfully supply for the international market. Moreover, we strive to continuously improve the customer experience through comprehensive technical support. High quality,rapid turnaround and personal support for all FineTest services are guaranteed. Should you have any problems,or any ideas on ways that we can improve our service,please feel free to call upon us.Thank you for your interest in FineTest products and we look forward to supplying you in the near future.